Bionic eye clinical trial results show long-term safety, efficacy vision-restoring implant

June 23, 2015
Figure A, The implanted portions of the Argus II System. Figure B, The external components of the Argus II System. Images in real time are captured by camera mounted on the glasses. The video processing unit down-samples and processes the image, converting it to stimulation patterns. Data and power are sent via radiofrequency link form the transmitter antenna on the glasses to the receiver antenna around the eye. A removable, rechargeable battery powers the system. Credit: Second Sight Medical Products, Inc.

The three-year clinical trial results of the retinal implant popularly known as the "bionic eye," have proven the long-term efficacy, safety and reliability of the device that restores vision in those blinded by a rare, degenerative eye disease. The findings show that the Argus II significantly improves visual function and quality of life for people blinded by retinitis pigmentosa. They are being published online today in Ophthalmology, the journal of the American Academy of Ophthalmology.

Retinitis pigmentosa is an incurable disease that affects about 1 in 4,000 Americans and causes slow vision loss that eventually leads to blindness. The Argus II system was designed to help provide patients who have lost their sight due to the disease with some useful vision. Through the device, patients with are able to see patterns of light that the brain learns to interpret as an image. The system uses a miniature video camera stored in the patient's glasses to send visual information to a small computerized video processing unit which can be stored in a pocket. This computer turns the image to electronic signals that are sent wirelessly to an electronic device implanted on the retina, the layer of light-sensing cells lining the back of the eye.

The Argus II received Food and Drug Administration (FDA) approval as a Humanitarian Use Device (HUD) in 2013, which is an approval specifically for devices intended to benefit small populations and/or rare conditions. In Europe Argus II received the CE Mark in 2011 and was launched commercially in Italy, Germany, France, Spain, The Netherlands, Switzerland and England.

To further evaluate the safety, reliability and benefit of the device, a clinical trial of 30 people, aged 28 to 77, was conducted in the United States and Europe. All of the study participants had little or no light perception in both eyes. The researchers conducted visual function tests using both a computer screen and real-world conditions, including finding and touching a door and identifying and following a line on the ground. A Functional Low-vision Observer Rated Assessment (FLORA) was also performed by independent visual rehabilitation experts at the request of the FDA to assess the impact of the Argus II system on the subjects' everyday lives, including extensive interviews and tasks performed around the home.

The visual function results indicated that up to 89 percent of the subjects performed significantly better with the device. The FLORA found that among the subjects, 80 percent received benefit from the system when considering both functional vision and patient-reported quality of life, and no subjects were affected negatively.

After one year, two-thirds of the subjects had not experienced device- or surgery-related serious adverse events. After three years, there were no device failures. Throughout the three years, 11 subjects experienced serious , most of which occurred soon after implantation and were successfully treated. One of these treatments, however, was to remove the device due to recurring erosion after the suture tab on the device became damaged.

"This study shows that the Argus II system is a viable treatment option for people profoundly blind due to retinitis pigmentosa - one that can make a meaningful difference in their lives and provides a benefit that can last over time," said Allen C. Ho, M.D., lead author of the study and director of the clinical retina research unit at Wills Eye Hospital. "I look forward to future studies with this technology which may make possible expansion of the intended use of the device, including treatment for other diseases and eye injuries."

Explore further: New device offers hope to people blinded due to incurable eye disorders

Related Stories

New device offers hope to people blinded due to incurable eye disorders

November 17, 2013
Research presented at the 117th Annual Meeting of the American Academy of Ophthalmology shows promising data about a device that helps people who have lost their vision due to a blinding genetic disease to recognize common ...

FDA recommends approval for Second Sight's Argus II retinal prosthesis system in the US

October 3, 2012
On Friday September 28, a U.S. Food and Drug Administration (FDA) Ophthalmic Devices Advisory Panel unanimously voted 19-0 that the probable benefit of the Argus II Retinal Prosthesis System outweighs the risks to health, ...

Eye implants make vision-restoring progress

July 18, 2012
(Medical Xpress) -- "I was blind once but now I can see.” The words are no longer the sole property of religious testimony and literature. Medical progress is being made in the restoration of vision as evidenced by Second ...

Photoelectric dye-coupled thin film as a novel type of retinal prosthesis

September 30, 2014
Eye doctor Dr. Toshihiko Matsuo and polymer science engineer Dr. Tetsuya Uchida have been developing a new type of retinal prosthesis that is based on a photoelectric dye. The photoelectric dye is an organic molecule that ...

Bionic eye gives hope to the blind

February 5, 2013
After years of research, the first bionic eye has seen the light of day in the United States, giving hope to the blind around the world.

Recommended for you

Researchers report startling glaucoma protein discovery

October 20, 2017
A discovery in a protein associated with glaucoma was so unheard of that for over two years, researchers ran it through a gauntlet of lab tests and published a new research paper on it. The tests validated what they initially ...

Curve-eye-ture: How to grow artificial corneas

October 19, 2017
Scientists at Newcastle University, UK, and the University of California have developed a new method to grow curved human corneas improving the quality and transparency - solely by controlling the behaviour of cells in a ...

Clinical study success for novel contact lens device aimed to improve glaucoma treatment

October 19, 2017
A novel contact lens device developed by University of Liverpool engineers to improve the treatment of glaucoma has been found to reliably track pressure changes in the eye and be wearable by people who took part in its first ...

Study indicates proof of concept for using a surrogate liquid biopsy to provide genetic profile of retinoblastoma tumors

October 12, 2017
Retinoblastoma is a tumor of the retina that generally affects children under 5 years of age. If not diagnosed early, retinoblastoma may result in loss of one or both eyes and can be fatal. Unlike most cancers that are diagnosed ...

Farsighted children struggle with attention, study finds

October 10, 2017
Farsighted preschoolers and kindergartners have a harder time paying attention and that could put them at risk of slipping behind in school, a new study suggests.

New drug reduces rate of progression of incurable eye disease

October 4, 2017
An international study including researchers from the Centre for Eye Research Australia (CERA) has found a way to slow the progression of dry age-related macular degeneration (AMD) - one of the most common causes of vision ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.